Strategic Shifts & Business Growth

With its 30th Illinois clinic, Westside Children's Therapy brings its integrated pediatric care model to Peoria, addressing a growing need for services.

The $204.6M deal creates an $8.3B regional powerhouse, raising questions about local impact, shareholder value, and the future of community banking.

With SEC approval, Auddia's transformative merger into AI holding company McCarthy Finney enters its final phase, setting the stage for a shareholder vote.

In a major industry shift, TPG Mortgage Trust will acquire Cherry Hill, creating a $9B REIT powerhouse aimed at scale, efficiency, and shareholder value.

In Bali's competitive market, Manguning Hotels gains an edge by pairing verified eco-credentials with a 'place-led' philosophy for authentic guest experiences.

The new blank check company debuts with a $100M war chest. A deep dive into its leadership, complex structure, and what its launch means for investors.

With $911M in the bank, Relay Therapeutics is aggressively advancing its precision drug zovegalisib, targeting both breast cancer and rare vascular anomalies.

Ad tech firm PubMatic stuns Wall Street with a major Q2 comeback, as its AI platform and CTV focus drive an 11% revenue surge and expanded profits.

Rigetti Computing posts a $52.6M quarterly loss but secures major partnerships and potential government funding, betting big on its long-term quantum strategy.

The luxury resale giant posted a record quarter and raised its 2026 forecast, but a wider GAAP loss tells a more complex story of strategic growth.

After Commerce.com's dismal Q2 results and stock plunge, AI-native rival Rezolve Ai declares its rejected merger proposal was the right path all along.

Emergen-C partners with Carl Radke's Soft Bar, tapping the functional mocktail trend. A strategic shift signals a new era for consumer health.

TOMS Capital challenges Voya Financial’s board over underperformance and strategic missteps, demanding a full strategic review to unlock shareholder value.

With spending up and losses widening, CG Oncology is leveraging its $1B cash reserve to push its promising bladder cancer drug toward a Q4 FDA submission.

Meduloc's $4M Series B, led by GenHenn Capital and backed by Andre Ethier, fuels the launch of its innovative nitinol implant for better fracture healing.

Ex-Spotify team secures $10M for Malachyte, bringing behavior AI to combat soaring acquisition costs and static online stores for a new era of retail.

The utility's strong Q2 results are fueled by massive energy demand from new data centers, prompting a $1B capital plan increase and promising regional growth.

Harrow's $100M deal for the first FDA-approved nasal spray for dry eye disease challenges the dominance of eye drops and reshapes its ophthalmic portfolio.

The hormone optimization leader's stock tumbles after Q2 results show a net loss and declining revenue, revealing the prolonged impact of its January recall.

The agentic customer platform posts 20% revenue growth and a return to profitability, yet a softer forecast reveals underlying market pressures.